Targets › ENV
9 programs from 5 companies in 23 trials: 12 Phase 1, 7 Phase 2, 4 Phase 3; Infectious disease; next expected readout Nov 2026.
Open in Phaseline: the race on ENV, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gilead Sciences | Teropavimab Anti-gp120 monoclonal antibody | ENV | Phase 3 | HIV Infections; HIV-1-infection; HIV-1 Infection | Mar 2029 |
| Gilead Sciences | Zinlirvimab Envelope protein inhibitor | ENV | Phase 3 | HIV Infections; HIV-1-infection; HIV-1 Infection; HIV/AIDS and Infections … | Mar 2029 |
| National Institute of Allergy and Infectious Diseases (NIAID) | VRC07-523LS Broadly neutralizing antibody against HIV-1 envelope protein | ENV | Phase 2 | HIV; Acute HIV Infection; HIV Infection; HIV-1 | Dec 2026 |
| TaiMed Biologics | TMB-380 Broadly neutralizing antibody (bNAb) against HIV; monoclonal antibody that binds to HIV en | ENV | Phase 2 | HIV -1 Infection | May 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 16055 NFL Delta Gly4 Env Protein Trimer HIV envelope protein (gp120/gp41) trimer vaccine immunogen | ENV | Phase 1 | HIV | Nov 2026 |
| University of California, San Francisco | [89]Zr-DFO-VRC01 Radiolabeled anti-HIV-1 envelope monoclonal antibody | ENV | Phase 1 | HIV-1-infection | Dec 2026 |
| National Institute of Allergy and Infectious Diseases (NIAID) | BG505 MD39.3 gp151 CD4KO mRNA HIV gp151 envelope trimer mRNA vaccine with CD4 binding site knock-out | ENV | Phase 1 | HIV Infections | Jun 2027 |
| National Institute of Allergy and Infectious Diseases (NIAID) | VRC01 Broadly neutralizing antibody against HIV-1 envelope glycoprotein gp120 | ENV | Phase 1 | HIV Infection | Jan 2028 |
| Steven Deeks | LVgp120duoCAR-T cells CAR-T cells expressing dual CAR targeting gp120, the envelope glycoprotein of HIV | GP120, ENV | Phase 1 | HIV Infections | Dec 2028 |
HIV (4) HIV Infection (4) HIV Infections (4) HIV-1-infection (4) HIV-1 (2) HIV-1 Infection (2) Acute HIV Infection (1) HIV/AIDS and Infections (1) HIV -1 Infection (1)
mixed (4), protein or peptide (2), small molecule (2), other (1)
National Institute of Allergy and Infectious Diseases (NIAID) (4) Gilead Sciences (2) TaiMed Biologics (1) Steven Deeks (1) University of California, San Francisco (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.